Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Zevalin Plus BuCyE High-dose Therapy in B-cell Non-Hodgkin's Lymphoma

This study has been completed.
Sponsor:
Collaborator:
Schering-Plough
Information provided by:
Asan Medical Center
ClinicalTrials.gov Identifier:
NCT00336843
First received: June 13, 2006
Last updated: February 7, 2011
Last verified: November 2008